Suppr超能文献

老年斑的历史:从阿尔茨海默病到淀粉样蛋白成像。

A History of Senile Plaques: From Alzheimer to Amyloid Imaging.

机构信息

From the Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Sun City, Arizona, USA.

出版信息

J Neuropathol Exp Neurol. 2022 May 20;81(6):387-413. doi: 10.1093/jnen/nlac030.

Abstract

Senile plaques have been studied in postmortem brains for more than 120 years and the resultant knowledge has not only helped us understand the etiology and pathogenesis of Alzheimer disease (AD), but has also pointed to possible modes of prevention and treatment. Within the last 15 years, it has become possible to image plaques in living subjects. This is arguably the single greatest advance in AD research since the identification of the Aβ peptide as the major plaque constituent. The limitations and potentialities of amyloid imaging are still not completely clear but are perhaps best glimpsed through the perspective gained from the accumulated postmortem histological studies. The basic morphological classification of plaques into neuritic, cored and diffuse has been supplemented by sophisticated immunohistochemical and biochemical analyses and increasingly detailed mapping of plaque brain distribution. Changes in plaque classification and staging have in turn contributed to changes in the definition and diagnostic criteria for AD. All of this information continues to be tested by clinicopathological correlations and it is through the insights thereby gained that we will best be able to employ the powerful tool of amyloid imaging.

摘要

老年斑在尸检大脑中已经被研究了 120 多年,由此产生的知识不仅帮助我们理解了阿尔茨海默病(AD)的病因和发病机制,而且还指出了可能的预防和治疗模式。在过去的 15 年里,已经有可能对活体受试者进行斑块成像。这可以说是自发现 Aβ肽作为主要斑块成分以来 AD 研究的最大进展。淀粉样蛋白成像的局限性和可能性尚不完全清楚,但通过对积累的尸检组织学研究获得的观点或许可以最好地了解。斑块的基本形态学分类为神经突、核心和弥漫性,现已通过复杂的免疫组织化学和生化分析以及越来越详细的斑块脑分布图谱得到补充。斑块分类和分期的变化反过来又导致了 AD 的定义和诊断标准的变化。所有这些信息都在继续通过临床病理相关性进行测试,正是通过由此获得的见解,我们才能最好地利用淀粉样蛋白成像这一强大工具。

相似文献

1
A History of Senile Plaques: From Alzheimer to Amyloid Imaging.
J Neuropathol Exp Neurol. 2022 May 20;81(6):387-413. doi: 10.1093/jnen/nlac030.
2
Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease.
Acta Neuropathol. 2020 Oct;140(4):463-476. doi: 10.1007/s00401-020-02175-1. Epub 2020 Aug 9.
5
Comparing amyloid-β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease.
Acta Neuropathol. 2021 Oct;142(4):689-706. doi: 10.1007/s00401-021-02342-y. Epub 2021 Jul 28.
6
7
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.
Brain. 2008 Jun;131(Pt 6):1630-45. doi: 10.1093/brain/awn016. Epub 2008 Mar 12.
8
9
Neuritic Plaques - Gateways to Understanding Alzheimer's Disease.
Mol Neurobiol. 2024 May;61(5):2808-2821. doi: 10.1007/s12035-023-03736-7. Epub 2023 Nov 8.
10
[Amyloid-plaque imaging of the brain using PET].
Ned Tijdschr Geneeskd. 2011;155:A2981.

引用本文的文献

1
Chemical imaging delineates Aβ plaque polymorphism across the Alzheimer's disease spectrum.
Nat Commun. 2025 Apr 24;16(1):3889. doi: 10.1038/s41467-025-59085-7.
2
Newer Therapeutic Approaches in Treating Alzheimer's Disease: A Comprehensive Review.
ACS Omega. 2025 Feb 3;10(6):5148-5171. doi: 10.1021/acsomega.4c05527. eCollection 2025 Feb 18.
3
Evidence for alpha-synuclein aggregation in older individuals with hyposmia: a cross-sectional study.
EBioMedicine. 2025 Feb;112:105567. doi: 10.1016/j.ebiom.2025.105567. Epub 2025 Feb 1.
6
Astrocyte-Neuron Interactions in Alzheimer's Disease.
Adv Neurobiol. 2024;39:345-382. doi: 10.1007/978-3-031-64839-7_14.
8
Alzheimer's disease: a review on the current trends of the effective diagnosis and therapeutics.
Front Aging Neurosci. 2024 Aug 9;16:1429211. doi: 10.3389/fnagi.2024.1429211. eCollection 2024.
10
The Promising Role of Selenium and Yeast in the Fight Against Protein Amyloidosis.
Biol Trace Elem Res. 2025 Mar;203(3):1251-1268. doi: 10.1007/s12011-024-04245-x. Epub 2024 Jun 3.

本文引用的文献

1
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering.
Alzheimers Res Ther. 2021 May 10;13(1):98. doi: 10.1186/s13195-021-00838-z.
2
Donanemab (LY3002813) dose-escalation study in Alzheimer's disease.
Alzheimers Dement (N Y). 2021 Feb 14;7(1):e12112. doi: 10.1002/trc2.12112. eCollection 2021.
3
Risk of Transmissibility From Neurodegenerative Disease-Associated Proteins: Experimental Knowns and Unknowns.
J Neuropathol Exp Neurol. 2020 Nov 1;79(11):1141-1146. doi: 10.1093/jnen/nlaa109.
4
Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease.
Alzheimers Dement. 2019 Jul;15(7):927-939. doi: 10.1016/j.jalz.2019.03.016. Epub 2019 Jun 4.
5
Estimation of amyloid distribution by [F]flutemetamol PET predicts the neuropathological phase of amyloid β-protein deposition.
Acta Neuropathol. 2018 Oct;136(4):557-567. doi: 10.1007/s00401-018-1897-9. Epub 2018 Aug 19.
6
Amyloid involvement in subcortical regions predicts cognitive decline.
Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2368-2376. doi: 10.1007/s00259-018-4081-5. Epub 2018 Jul 6.
7
PET staging of amyloidosis using striatum.
Alzheimers Dement. 2018 Oct;14(10):1281-1292. doi: 10.1016/j.jalz.2018.04.011. Epub 2018 May 21.
10
In vivo staging of regional amyloid deposition.
Neurology. 2017 Nov 14;89(20):2031-2038. doi: 10.1212/WNL.0000000000004643. Epub 2017 Oct 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验